Levamisole in chronic hepatitis: A favorable trend is not enough
Jay H. Hoofnagle – 1 May 1987 – A double‐blind, randomized, controlled trial has been undertaken to evaluate treatment of chronic hepatitis type B with levamisole. Ten patients received levamisole (150 mg/day, 3 days/wk) and 10 received placebo until seroconversion to antibody to hepatitis B e antigen eventually occurred, or for a maximum of 18 mo.